1. any clinical signs and symptoms consistent with covid-19, eg, fever, dry cough, dyspnea, sore throat, fatigue for ≥ 5 days or confirmed covid-19 infection by appropriate laboratory test within 28 days prior to screening. prior covid-19 infection is not an exclusion. 2. history or current hospitalization for worsening disease during the one month prior to screening, with no change in condition at the time of study enrollment as judged by the investigator. 3. current need for hospitalization or immediate medical attention in a clinic or emergency room service in the clinical opinion of the investigator. 4. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. 5. known history of allergy to any component of the imp formulation. 6. history of clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following iv infusions or venepuncture. 7. any other significant disease, disorder, or finding that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data 8. any co-morbidity requiring surgery within 7 days prior to study entry, or that is considered life-threatening in the opinion of the investigator within 30 days prior to study entry. 9 any prior receipt of investigational or licensed mab or other biologic indicated for the prevention or treatment of sars-cov-2 or covid-19 within 5 half-lives prior to screening or expected administration immediately after enrollment. 10 have received a covid-19 vaccination ≤ 14 days before day 1 or plan to receive a covid-19 vaccination ≤ 14 days after day 1 (such participants can subsequently be included in the study once they have reached \> 14 days after their last dose of vaccine). 11 receipt of convalescent covid-19 plasma treatment within 90 days prior to screening. 12 receipt of any imp in the preceding 90 days or 5 half-lives, whichever is longer, or expected receipt of imp during the period of study follow-up, or concurrent participation in another interventional study. 13 judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements. 14 for women only - currently pregnant (confirmed with positive pregnancy test) or breastfeeding. 15 previous randomization in the present study. 16 blood drawn in excess of a total of 450 ml (1 unit) for any reason within 30 days prior to randomization. 17 employees of the sponsor involved in planning executing, supervising, or reviewing the azd7442 program, clinical study site staff, or any other individuals involved with the conduct of the study, or immediate family members of such individuals. 18 in nations, states, or other jurisdictions that for legal or ethical reasons bar the enrollment of participants who lack capacity to provide their own informed consent, such subjects are excluded.

1. any clinical signs and symptoms consistent with covid-19, eg, fever, dry cough, dyspnea, sore throat, fatigue for ≥ 5 days or confirmed covid-19 infection by appropriate laboratory test within 28 days prior to screening. prior covid-19 infection is not an exclusion. 2. history or current hospitalization for worsening disease during the one month prior to screening, with no change in condition at the time of study enrollment as judged by the investigator. 3. current need for hospitalization or immediate medical attention in a clinic or emergency room service in the clinical opinion of the investigator. 4. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. 5. known history of allergy to any component of the imp formulation. 6. history of clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following iv infusions or venepuncture. 7. any other significant disease, disorder, or finding that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data 8. any co-morbidity requiring surgery within 7 days prior to study entry, or that is considered life-threatening in the opinion of the investigator within 30 days prior to study entry. 9 any prior receipt of investigational or licensed mab or other biologic indicated for the prevention or treatment of sars-cov-2 or covid-19 within 5 half-lives prior to screening or expected administration immediately after enrollment. 10 have received a covid-19 vaccination ≤ 14 days before day 1 or plan to receive a covid-19 vaccination ≤ 14 days after day 1 (such participants can subsequently be included in the study once they have reached \> 14 days after their last dose of vaccine). 11 receipt of convalescent covid-19 plasma treatment within 90 days prior to screening. 12 receipt of any imp in the preceding 90 days or 5 half-lives, whichever is longer, or expected receipt of imp during the period of study follow-up, or concurrent participation in another interventional study. 13 judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements. 14 for women only - currently pregnant (confirmed with positive pregnancy test) or breastfeeding. 15 previous randomization in the present study. 16 blood drawn in excess of a total of 450 ml (1 unit) for any reason within 30 days prior to randomization. 17 employees of the sponsor involved in planning executing, supervising, or reviewing the azd7442 program, clinical study site staff, or any other individuals involved with the conduct of the study, or immediate family members of such individuals. 18 in nations, states, or other jurisdictions that for legal or ethical reasons bar the enrollment of participants who lack capacity to provide their own informed consent, such subjects are excluded.

any clinical signs and symptoms consistent with covid-19, eg, fever, dry cough, dyspnea, sore throat, fatigue for ≥ 5 days or confirmed covid-19 infection by appropriate laboratory test within 28 days prior to screening. prior covid-19 infection is not an exclusion. history or current hospitalization for worsening disease during the one month prior to screening, with no change in condition at the time of study enrollment as judged by the investigator. current need for hospitalization or immediate medical attention in a clinic or emergency room service in the clinical opinion of the investigator. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. known history of allergy to any component of the imp formulation. history of clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following iv infusions or venepuncture. any other significant disease, disorder, or finding that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data any co-morbidity requiring surgery within 7 days prior to study entry, or that is considered life-threatening in the opinion of the investigator within 30 days prior to study entry. 9 any prior receipt of investigational or licensed mab or other biologic indicated for the prevention or treatment of sars-cov-2 or covid-19 within 5 half-lives prior to screening or expected administration immediately after enrollment. 10 have received a covid-19 vaccination ≤ 14 days before day 1 or plan to receive a covid-19 vaccination ≤ 14 days after day 1 (such participants can subsequently be included in the study once they have reached > 14 days after their last dose of vaccine). 11 receipt of convalescent covid-19 plasma treatment within 90 days prior to screening. 12 receipt of any imp in the preceding 90 days or 5 half-lives, whichever is longer, or expected receipt of imp during the period of study follow-up, or concurrent participation in another interventional study. 13 judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements. 14 for women only - currently pregnant (confirmed with positive pregnancy test) or breastfeeding. 15 previous randomization in the present study. 16 blood drawn in excess of a total of 450 ml (1 unit) for any reason within 30 days prior to randomization. 17 employees of the sponsor involved in planning executing, supervising, or reviewing the azd7442 program, clinical study site staff, or any other individuals involved with the conduct of the study, or immediate family members of such individuals. 18 in nations, states, or other jurisdictions that for legal or ethical reasons bar the enrollment of participants who lack capacity to provide their own informed consent, such subjects are excluded.

any clinical signs and symptoms consistent with covid-19, eg, fever, dry cough, dyspnea, sore throat, fatigue for ≥ 5 days or confirmed covid-19 infection by appropriate laboratory test within 28 days prior to screening. prior covid-19 infection is not an exclusion. history or current hospitalization for worsening disease during the one month prior to screening, with no change in condition at the time of study enrollment as judged by the investigator. current need for hospitalization or immediate medical attention in a clinic or emergency room service in the clinical opinion of the investigator. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. known history of allergy to any component of the imp formulation. history of clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following iv infusions or venepuncture. any other significant disease, disorder, or finding that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data any co-morbidity requiring surgery within 7 days prior to study entry, or that is considered life-threatening in the opinion of the investigator within 30 days prior to study entry. 9 any prior receipt of investigational or licensed mab or other biologic indicated for the prevention or treatment of sars-cov-2 or covid-19 within 5 half-lives prior to screening or expected administration immediately after enrollment. 10 have received a covid-19 vaccination ≤ 14 days before day 1 or plan to receive a covid-19 vaccination ≤ 14 days after day 1 (such participants can subsequently be included in the study once they have reached > 14 days after their last dose of vaccine). 11 receipt of convalescent covid-19 plasma treatment within 90 days prior to screening. 12 receipt of any imp in the preceding 90 days or 5 half-lives, whichever is longer, or expected receipt of imp during the period of study follow-up, or concurrent participation in another interventional study. 13 judgment by the investigator that the participant should not participate in the study if the participant is unlikely to comply with study procedures, restrictions, and requirements. 14 for women only - currently pregnant (confirmed with positive pregnancy test) or breastfeeding. 15 previous randomization in the present study. 16 blood drawn in excess of a total of 450 ml (1 unit) for any reason within 30 days prior to randomization. 17 employees of the sponsor involved in planning executing, supervising, or reviewing the azd7442 program, clinical study site staff, or any other individuals involved with the conduct of the study, or immediate family members of such individuals. 18 in nations, states, or other jurisdictions that for legal or ethical reasons bar the enrollment of participants who lack capacity to provide their own informed consent, such subjects are excluded.

any clinical signs and symptoms consistent with covid-19, eg, fever, dry cough, dyspnea, sore throat, fatigue for ≥ 5 days or confirmed covid-19 infection by appropriate laboratory test within 28 days prior to screening. history or current hospitalization for worsening disease during the one month prior to screening, with no change in condition at the time of study enrollment as judged by the investigator. current need for hospitalization or immediate medical attention in a clinic or emergency room service in the clinical opinion of the investigator. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. known history of allergy to any component of the imp formulation. history of clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following iv infusions or venepuncture. any other significant disease, disorder, or finding that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data any co-morbidity requiring surgery within 7 days prior to study entry, or that is considered life-threatening in the opinion of the investigator within 30 days prior to study entry.

any clinical signs and symptoms consistent with covid-19, eg, fever, dry cough, dyspnea, sore throat, fatigue for ≥ 5 days or confirmed covid-19 infection by appropriate laboratory test within 28 days prior to screening. history or current hospitalization for worsening disease during the one month prior to screening, with no change in condition at the time of study enrollment as judged by the investigator. current need for hospitalization or immediate medical attention in a clinic or emergency room service in the clinical opinion of the investigator. previous hypersensitivity, infusion-related reaction, or severe adverse reaction following administration of a mab. known history of allergy to any component of the imp formulation. history of clinically significant bleeding disorder (eg, factor deficiency, coagulopathy, or platelet disorder), or prior history of significant bleeding or bruising following iv infusions or venepuncture. any other significant disease, disorder, or finding that may significantly increase the risk to the participant because of participation in the study, affect the ability of the participant to participate in the study, or impair interpretation of the study data any co-morbidity requiring surgery within 7 days prior to study entry, or that is considered life-threatening in the opinion of the investigator within 30 days prior to study entry.